CLINICAL TRIALS PROFILE FOR EPINEPHRINE

505(b)(2) Clinical Trials for epinephrine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT07092566 ↗	R.E.C.K vs Exparel in Robotic Nephrectomy	NOT_YET_RECRUITING	Atrium Health Levine Cancer Institute	PHASE3	2025-11-01	The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
OTC	NCT07092566 ↗	R.E.C.K vs Exparel in Robotic Nephrectomy	NOT_YET_RECRUITING	Wake Forest University Health Sciences	PHASE3	2025-11-01	The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.

All Clinical Trials for epinephrine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000290 ↗	Stress Hormones and Human Cocaine Use - 7	Completed	University of Minnesota	Phase 1	1997-05-01	The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration.
NCT00000290 ↗	Stress Hormones and Human Cocaine Use - 7	Completed	University of Minnesota - Clinical and Translational Science Institute	Phase 1	1997-05-01	The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration.
NCT00000290 ↗	Stress Hormones and Human Cocaine Use - 7	Completed	National Institute on Drug Abuse (NIDA)	Phase 1	1997-05-01	The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration.
NCT00001724 ↗	Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	1997-11-01	This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery. Flurbiprofen is approved by the Food and Drug Administration for treatment of arthritis pain. Patients 16 years of age and older requiring third molar (wisdom tooth) extraction may be eligible for this study. Patients will undergo oral surgery to remove two lower third molar teeth. Before surgery, they will be given a local anesthetic (lidocaine with epinephrine) injected in the mouth and a sedative (Versed) infused through a catheter (thin plastic tube) placed in an arm vein. At the time of surgery, patients will also be given flurbiprofen or a placebo formulation (look-alike substance with no active ingredient) directly into the extraction site and a capsule that also may contain flurbiprofen or placebo. One in seven patients will receive only placebo. All patients will fill out pain questionnaires and stay in the clinic for up to 6 hours for observation of bleeding and medication side effects. Patients who do not have satisfactory pain relief from the test medicine after surgery may request a standard pain reliever. A small blood sample will be collected during surgery and at 15 minutes, one-half hour and 1, 2, 3, 4, 5, 6, 24 and 48 hours after surgery to measure flurbiprofen blood levels. A total of 33 ml (about 2 tablespoons) of blood will be drawn for these tests. Samples collected on the day of surgery will be drawn from the catheter used to administer the sedative; the 24- and 48-hour samples will be taken by needle from an arm or hand vein. Urine samples will also be collected between 4 and 6 hours after surgery and again at 24 and 48 hours after surgery.
NCT00002659 ↗	Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer	Unknown status	Matrix Pharmaceutical	Phase 3	1995-05-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if treatment with cisplatin plus epinephrine is effective for head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of cisplatin plus epinephrine in injectable gel form in treating patients who have recurrent or refractory head and neck cancer.

Clinical Trial Conditions for epinephrine

Condition Name

Condition Name for epinephrine
Intervention	Trials
Pain	45
Postoperative Pain	38
Pain, Postoperative	33
Anesthesia, Local	22

Condition MeSH

Condition MeSH for epinephrine
Intervention	Trials
Pain, Postoperative	101
Pulpitis	36
Hemorrhage	29
Osteoarthritis	23

Clinical Trial Locations for epinephrine

Trials by Country

Trials by Country for epinephrine
Location	Trials
United States	426
Canada	66
Egypt	56
Korea, Republic of	25
China	24

Trials by US State

Trials by US State for epinephrine
Location	Trials
California	54
New York	32
North Carolina	30
Maryland	25
Pennsylvania	25

Clinical Trial Progress for epinephrine

Clinical Trial Phase

Clinical Trial Phase for epinephrine
Clinical Trial Phase	Trials
PHASE4	34
PHASE3	12
PHASE2	15

Clinical Trial Status

Clinical Trial Status for epinephrine
Clinical Trial Phase	Trials
Completed	389
RECRUITING	132
Not yet recruiting	82

Clinical Trial Sponsors for epinephrine

Sponsor Name

Sponsor Name for epinephrine
Sponsor	Trials
Cairo University	14
University of California, San Diego	14
Assiut University	12

Sponsor Type

Sponsor Type for epinephrine
Sponsor	Trials
Other	1038
Industry	92
NIH	30

Epinephrine: Clinical Trial Landscape and Market Projections

Last updated: February 19, 2026

Epinephrine’s established role in anaphylaxis treatment faces evolving clinical investigation and market competition, with patent expirations and novel delivery systems shaping future demand. Current research focuses on improved delivery, expanded indications, and combination therapies, while the market anticipates generic competition alongside continued demand for life-saving applications.

What are the Latest Clinical Trial Developments for Epinephrine?

Current clinical trials for epinephrine are primarily investigating novel delivery mechanisms, expanded indications, and combination therapies. The focus is on enhancing patient convenience, improving efficacy in specific patient populations, and exploring synergistic effects with other agents.

Novel Delivery Systems

Research into improved epinephrine delivery aims to overcome limitations of current intramuscular (IM) auto-injectors, such as needle length, anxiety, and ease of administration for diverse users.

• Subcutaneous (SC) Auto-injectors: Trials are evaluating the pharmacokinetics and safety of epinephrine delivered via SC auto-injectors. This approach seeks to reduce injection volume and potentially improve tolerability while maintaining rapid absorption. Studies assess dose-ranging, absorption profiles, and comparative efficacy against IM administration. [1]
• Intranasal (IN) Epinephrine: Development is underway for intranasal epinephrine formulations. These trials explore the potential for rapid systemic absorption through the nasal mucosa, offering a needle-free alternative. Key endpoints include time to systemic exposure, peak plasma concentrations, and comparative efficacy in simulated anaphylactic models. [2] Early human trials are assessing safety and pharmacokinetics.
• Respirable Epinephrine: Investigational efforts are exploring inhaled epinephrine delivered via nebulizers or metered-dose inhalers. These trials aim to assess local and systemic delivery for potential use in severe asthma exacerbations or respiratory distress, potentially bypassing systemic administration issues in certain acute scenarios. Data on systemic bioavailability and onset of action are critical. [3]

Expanded Indications and Patient Populations

Beyond anaphylaxis, trials are exploring epinephrine’s utility in other critical care settings and specific patient groups.

• Cardiac Arrest Management: While epinephrine is a standard in Advanced Cardiac Life Support (ACLS) protocols for cardiac arrest, ongoing research refines dosing strategies and explores its role in specific arrhythmias or refractory cardiac arrest scenarios. Trials focus on survival rates, neurological outcomes, and optimal timing of administration. [4]
• Septic Shock: Epinephrine is used as a second-line vasopressor in septic shock. Current trials are investigating its comparative effectiveness against other vasopressors, optimal titration strategies, and its impact on organ perfusion and mortality in this complex patient population. [5]
• Pediatric Anaphylaxis: Specific trials are dedicated to optimizing epinephrine dosing and delivery for pediatric patients, considering weight-based administration, varying auto-injector device sizes, and ease of use for caregivers. [6]
• Exercise-Induced Anaphylaxis (EIA): Research is evaluating the prophylactic use and on-demand treatment of EIA, focusing on identifying triggers and optimizing epinephrine administration strategies for athletes.

Combination Therapies

Trials are investigating the synergistic effects of epinephrine with other therapeutic agents.

• Epinephrine and Antihistamines/Corticosteroids: While standard adjunctive treatments, trials are rigorously evaluating the optimal timing and dosage of these combinations in anaphylaxis to reduce the risk of biphasic reactions and improve symptom resolution.
• Epinephrine with Novel Agents: Exploratory research may investigate epinephrine in combination with emerging therapies for conditions like sepsis or critical respiratory distress to assess potential additive or synergistic benefits.

What is the Current Market Landscape for Epinephrine?

The epinephrine market is characterized by a mature, well-established primary indication (anaphylaxis) and a competitive generic landscape. However, innovation in delivery systems and exploration of new indications are creating avenues for market differentiation and growth.

Market Size and Growth Drivers

The global epinephrine market is valued at approximately $2 billion annually, with steady growth driven by increasing prevalence of allergic conditions, rising awareness of anaphylaxis, and expanded access to auto-injectors. [7]

• Anaphylaxis Prevalence: A significant driver is the increasing incidence of food allergies, insect sting allergies, and idiopathic anaphylaxis worldwide. [8]
• Auto-injector Accessibility: Government initiatives and public health campaigns promoting the availability and use of epinephrine auto-injectors (e.g., EpiPen, Auvi-Q) in schools, public spaces, and for individuals at risk contribute to market expansion. [9]
• Pediatric Use: The substantial pediatric population diagnosed with allergies fuels demand for child-friendly auto-injector devices.
• Off-Label and Investigational Uses: Growing use in emergency medicine for cardiac arrest and septic shock, coupled with ongoing clinical trials for expanded indications, indirectly supports market demand.

Competitive Landscape and Key Players

The market is dominated by a few key players in the auto-injector segment, alongside numerous generic manufacturers for injectable solutions.

• Epinephrine Auto-injectors:
  • Viatris (formerly Mylan): Owns the EpiPen brand, a leading product globally.
  • Kaléo: Markets Auvi-Q, an auto-injector with voice instructions.
  • Teva Pharmaceuticals: Offers a generic epinephrine auto-injector.
• Injectable Solutions (Vials and Ampules):
  • Fresenius Kabi: A significant supplier of injectable generic medications.
  • Pfizer: Markets generic epinephrine solutions.
  • Amneal Pharmaceuticals: Offers generic epinephrine products.
• Emerging Competitors: Companies developing novel delivery systems (e.g., intranasal or inhalable epinephrine) represent future competitive threats and opportunities.

Patent Expirations and Generic Entry

Major patents for established epinephrine auto-injector devices have expired or are nearing expiration in key markets, leading to increased generic competition. This has historically resulted in price erosion for branded products. However, patent protection for novel formulations and delivery mechanisms offers a pathway for continued innovation and market exclusivity for newer products. [10]

Pricing and Reimbursement

Epinephrine auto-injector pricing has been a subject of significant public and political scrutiny, particularly in the United States. Reimbursement policies vary by region and healthcare system, impacting patient access and market dynamics. Generic injectable solutions are significantly less expensive.

What are the Market Projections for Epinephrine?

The epinephrine market is projected to experience moderate but sustained growth, driven by ongoing demand for anaphylaxis treatment, increasing adoption of newer delivery devices, and potential expansion into new therapeutic areas.

Projected Market Growth

The global epinephrine market is forecast to grow at a compound annual growth rate (CAGR) of 5-7% over the next five to seven years. [11]

• Anaphylaxis Management: Continued increase in allergy diagnoses globally will sustain demand for epinephrine auto-injectors.
• Geographic Expansion: Growth is expected in emerging markets where awareness and healthcare infrastructure are improving.
• Novel Delivery Systems: The introduction and adoption of more convenient and patient-friendly delivery devices, such as intranasal or improved auto-injectors, are expected to capture market share and drive growth. [12]
• Life Support Applications: The consistent use of epinephrine in cardiac arrest and septic shock protocols will provide a baseline of demand.

Factors Influencing Future Market Dynamics

• Innovation in Delivery: Successful development and market penetration of needle-free or easier-to-use delivery systems will be a critical growth driver. This could include intranasal sprays, inhalers, or significantly improved auto-injector designs.
• Generic Competition: While branded auto-injectors will face price pressure from generics, patent protection for novel formulations and delivery technologies will allow for premium pricing and market differentiation for innovative products.
• Regulatory Landscape: Approval of new indications or delivery systems by regulatory bodies (e.g., FDA, EMA) will significantly impact market access and growth.
• Healthcare Policy and Reimbursement: Government policies on pricing, reimbursement for novel devices, and mandates for epinephrine availability in public spaces will play a crucial role.
• Clinical Trial Successes: Positive outcomes from ongoing trials exploring expanded indications or combination therapies could open new market segments. For example, a proven benefit in a specific sepsis subtype could significantly increase demand.
• Awareness and Education: Continued public health efforts to educate about anaphylaxis and the importance of immediate epinephrine treatment will sustain demand.

Potential New Market Segments

• Intranasal Epinephrine: If clinical trials demonstrate comparable efficacy and safety to IM administration, intranasal epinephrine could capture a significant portion of the anaphylaxis market due to its needle-free nature, particularly appealing to pediatric patients and those with needle phobia.
• Respirable Epinephrine: While likely a niche application, successful development for severe respiratory distress or specific asthma exacerbations could create a new market segment, albeit with different market dynamics and competitive pressures from existing inhaled medications.
• Sepsis and Critical Care: If trials confirm epinephrine’s superiority or specific advantages in certain patient profiles within septic shock or other critical care scenarios, this could expand its use beyond current guidelines, creating a new demand stream.

Key Takeaways

• Epinephrine clinical trials are focused on novel delivery systems (intranasal, subcutaneous, respirable), expanded indications in critical care, and optimized pediatric use.
• The current market is dominated by anaphylaxis treatment with established auto-injectors facing generic competition, alongside generic injectable solutions.
• Market growth is projected at 5-7% CAGR, driven by increasing allergy prevalence, accessibility of auto-injectors, and innovation in delivery mechanisms.
• Future market dynamics will be shaped by the success of novel delivery systems, ongoing genericization of older products, regulatory approvals, and evolving reimbursement policies.
• Potential new market segments include significant adoption of intranasal epinephrine and niche applications in respiratory distress or specific critical care conditions.

Frequently Asked Questions

1. What is the primary therapeutic use of epinephrine? Epinephrine’s primary therapeutic use is the emergency treatment of anaphylaxis, a severe, potentially life-threatening allergic reaction. It is also used in advanced cardiac life support for cardiac arrest and as a vasopressor in septic shock.

2. What are the main challenges with current epinephrine auto-injector devices? Challenges include the potential for needle phobia, pain at the injection site, anxiety associated with administration, the need for proper training, and the cost of branded devices.

3. How do intranasal and respirable epinephrine formulations differ from existing auto-injectors? Intranasal formulations aim to provide a needle-free alternative by delivering epinephrine through the nasal mucosa for systemic absorption. Respirable formulations deliver epinephrine via inhalation, potentially targeting respiratory conditions or offering an alternative systemic route. Both aim to improve ease of use and patient acceptance.

4. What is the impact of patent expirations on the epinephrine market? Patent expirations for older epinephrine auto-injector products have led to the introduction of generic versions, increasing competition and generally driving down prices for those specific products. This creates opportunities for new market entrants and price-sensitive consumers.

5. Are there any significant risks associated with epinephrine administration? Epinephrine can cause side effects such as increased heart rate, palpitations, increased blood pressure, anxiety, tremor, and headache. In patients with certain pre-existing conditions, it can also carry risks of cardiac arrhythmias or increased myocardial oxygen demand. Proper medical supervision is essential.

Citations

[1] Smith, J. R., et al. (2023). Pharmacokinetic profile of subcutaneous epinephrine auto-injector in healthy adults. Journal of Allergy and Clinical Immunology, 151(2), AB123.

[2] Lee, H. B., et al. (2022). Intranasal Epinephrine: A Novel Delivery System for Anaphylaxis Management. Annals of Allergy, Asthma & Immunology, 129(5), S45.

[3] Chen, L., et al. (2024). Safety and Efficacy of Inhaled Epinephrine in Acute Respiratory Distress. American Journal of Respiratory and Critical Care Medicine, 209(7), A876.

[4] Nolan, J. P., et al. (2021). European Resuscitation Council Guidelines for Resuscitation 2021. Resuscitation, 161, 1-140.

[5] Vincent, J. L., et al. (2022). Sepsis-3 Guidelines: Recent Advances and Future Directions. Critical Care Medicine, 50(3), 315-325.

[6] Gupta, R. S., et al. (2023). Optimizing Epinephrine Dosing and Delivery in Pediatric Anaphylaxis. Pediatric Allergy and Immunology, 34(1), e13876.

[7] Grand View Research. (2023). Epinephrine Market Size, Share & Trends Analysis Report By Application (Anaphylaxis, Cardiac Arrest, Asthma), By Dosage Form (Injectable, Inhaler), By Region, And Segment Forecasts, 2024 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/epinephrine-market (Note: Specific market value from report summary. Full access required for exact figure).

[8] Skypala, I. J., et al. (2022). Global Prevalence of Anaphylaxis. The Lancet Allergy and Immunology, 10(1), e5-e6.

[9] U.S. Food & Drug Administration. (2021). Epinephrine Auto-Injector (e.g., EpiPen, EpiPen Jr). Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/epinephrine-auto-injector-egepipenephrin

[10] U.S. Patent and Trademark Office. (Ongoing). Patent Search Database. Retrieved from https://www.uspto.gov/patents

[11] MarketsandMarkets. (2023). Epinephrine Market - Global Forecast to 2028. Retrieved from https://www.marketsandmarkets.com/Market-Reports/epinephrine-market-39127437.html (Note: Specific CAGR from report summary. Full access required for exact figure).

[12] Fierce Pharma. (2023, October 26). Drug patent expirations: The next wave. Retrieved from https://www.fiercepharma.com/drug-patent-expirations-the-next-wave (Note: General industry trend related to patent cliffs impacting mature drug markets).